These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 9150655)

  • 1. Xalatan difficulties.
    Sutton B
    J Am Optom Assoc; 1997 Apr; 68(4):214. PubMed ID: 9150655
    [No Abstract]   [Full Text] [Related]  

  • 2. Two new drugs for glaucoma.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):117-120. PubMed ID: 30036347
    [No Abstract]   [Full Text] [Related]  

  • 3. Serious spinal sequelae following the use of eye drops.
    Park JC; Jones DH
    Eye (Lond); 2010 Jun; 24(6):1109. PubMed ID: 19876072
    [No Abstract]   [Full Text] [Related]  

  • 4. [Latanoprost (Xalatan) and a systemic respiratory effect? Apropos of a case].
    Veyrac G; Chiffoleau A; Cellerin L; Larousse C; Bourin M
    Therapie; 1999; 54(4):494-6. PubMed ID: 10667120
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the stability, efficacy, and adverse effect profile of the innovator 0.005% latanoprost ophthalmic solution and a novel cyclodextrin-containing formulation.
    Gonzalez JR; Baiza-Duran L; Quintana-Hau J; Tornero-Montaño R; Castaneda-Hernandez G; Ortiz M; Alarcon-Oceguera F; Beltran-Loustaunau M; Cortez-Gastelum M; Garcidueñas-Mejia J; Gomez-Bastar P; Jimenez-Roman J; Korder-Ortega V; Paczka-Zapata J; Torres-Segura M; Velasco-Gallegos G
    J Clin Pharmacol; 2007 Jan; 47(1):121-6. PubMed ID: 17192510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxic epidermal necrolysis secondary to timolol, dorzolamide, and latanoprost eyedrops.
    Flórez A; Rosón E; Conde A; González B; García-Doval I; de la Torre C; Cruces M
    J Am Acad Dermatol; 2005 Nov; 53(5):909-11. PubMed ID: 16243161
    [No Abstract]   [Full Text] [Related]  

  • 7. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
    García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J
    Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension.
    Chiba T; Kashiwagi K; Chiba N; Tsukahara S
    Br J Ophthalmol; 2006 Mar; 90(3):314-7. PubMed ID: 16488953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuroprotection and vasoprotection in glaucoma].
    Ignat F
    Oftalmologia; 2004; 48(2):5-14. PubMed ID: 15341092
    [No Abstract]   [Full Text] [Related]  

  • 12. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture.
    Stjernschantz JW
    Invest Ophthalmol Vis Sci; 2001 May; 42(6):1134-45. PubMed ID: 11328719
    [No Abstract]   [Full Text] [Related]  

  • 13. Cystoid macular edema associated with the use of latanoprost.
    Gaddie IB; Bennett DW
    J Am Optom Assoc; 1998 Feb; 69(2):122-8. PubMed ID: 9549261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Side effects of antiglaucoma eye drops].
    Otori Y
    Nippon Ganka Gakkai Zasshi; 2006 Aug; 110(8):571-3. PubMed ID: 16972647
    [No Abstract]   [Full Text] [Related]  

  • 15. Systemic side effects of topical latanoprost.
    Rajan MS; Syam P; Liu C
    Eye (Lond); 2003 Apr; 17(3):442-4. PubMed ID: 12724721
    [No Abstract]   [Full Text] [Related]  

  • 16. Allergic contact dermatitis caused by topical eye drops.
    Spaeth GL
    Am J Ophthalmol; 2006 Oct; 142(4):706. PubMed ID: 17011880
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch to latanoprost monotherapy from combined treatment with beta-antagonist and other antiglaucoma agents in patients with glaucoma or ocular hypertension.
    Ito K; Goto R; Matsunaga K; Sugimoto K; Uji Y
    Jpn J Ophthalmol; 2004; 48(3):276-80. PubMed ID: 15175922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Topical prostaglandins influence over cornea--preliminary report].
    Wierzbowska J; Stankiewicz A
    Klin Oczna; 2006; 108(10-12):479-81. PubMed ID: 17455732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Xalatan--a new way to treat open angle glaucoma and intraocular hypertension. Physiologic enhancement of the flow of anterior chamber fluid].
    Klin Monbl Augenheilkd; 1997 Aug; 211(2 Suppl Xalatan):1-4. PubMed ID: 9330658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.